Polymeric, degradable drug-eluting stents and coatings
View Patent ↗Absorbable stents and absorbable stent coatings have been developed with improved properties. These devices preferably comprise biocompatible copolymers or homopolymers of 4-hydroxybutyrate, and optionally poly-L-lactic acid and other absorbable polymers and additives. Compositions of these materials can be used to make absorbable stents that provide advantageous radial strengths, resistance to recoil and creep, can be plastically expanded on a balloon catheter, and can be deployed rapidly in vivo. Stent coatings derived from these materials provide biocompatible, uniform coatings that are ductile, and can be expanded without the coating cracking and/or delarmnating and can be used as a coating matrix for drug incorporation.
1. A biocompatible stent comprising a base coat adhered to the stent, and optionally a top coat, wherein the stent
has a radial recoil of less than 10%,
is expandable rapidly in viva using a balloon pressure of 4 to 16 bar without cracking of the stent or stent base coat, or other mechanical failure,
does not exhibit any significant creep at 100 mmHg for 7 days,
does not shorten significantly upon expansion; and
has struts, constructed with smooth strut edges with strut thicknesses of less than 300 microns, and
wherein the base coat comprises a blend of poly-4-hydroxybutyrate (P(4HB)) and poly(L-lactide) (PLLA), and one or more nanoparticulate or microparticulate agents.
2. The stent of claim 1 , wherein the ratio of P(4HB) to PLLA in the blend is selected from the group consisting of 95/5 P(4HB)/PLLA w/w, 90/10 P(4HB)/PLLA w/w, 85/15 P(4HB)/PLLA w/w, 80/20 P(4HB)/PLLA w/w, 75/25 P(4HB)/PLLA w/w, 70/30 P(4HB)/PLLA w/w, 65/35 P(4HB)/PLLA w/w, 60/40 P(4HB)/PLLA w/w, 55/45 P(4HB)/PLLA w/w, 50/50 P(4HB)/PLLA w/w, 45/55 P(4HB)/PLLA w/w, 40/60 P(4HB)/PLLA w/w, 35/65 P(4HB)/PLLA w/w, and 30/70 P(4HB)/PLLA w/w.
3. The stent of claim 1 , wherein the base coat has a thickness of from about 10 microns to about 50 microns.
4. The stent of claim 1 , comprising one or more therapeutic, diagnostic or prophylactic agents selected from the group consisting of anti-inflammatory agents, immunomodulators, antithrombin agents, anti-proliferative agents, anti-restenosis agents, anti-migratory agents, extracellular matrix modulators, antiplatelet agents, wound healing agents, endothelialization promoters, and combinations thereof.
5. The stent of claim 4 , wherein the concentration of the one or more therapeutic, diagnostic or prophylactic agents in the base coat is about 2 μg/mm 2 .
6. The stent of claim 4 , wherein the one or more therapeutic, diagnostic or prophylactic agents is an anti-restenosis agent selected from the group consisting of Sirolimus (Rapamycin), Tacrolimus, Biorest, Mizoribin, Cyclosporin, Interferon γ1b, Leflunomid, Tranilast, Corticosteroide, Mycophenolic acid, Biphosphonate, and combinations thereof.
7. The stent of claim 6 , wherein the anti-restenosis agent is rapamycin.
8. The stent of claim 1 , wherein the stent comprises a top coat.
9. The stent of claim 8 , wherein the top coat comprises P(4HB) or a blend of P(4HB) and PLLA.
10. The stent of claim 9 wherein the ratio of P(4HB) to PLLA in the top coat is selected from the group consisting of 95/5 P(4HB)/PLLA w/w, 90/10 P(4HB)/PLLA w/w, 85/15 P(4HB)/PLLA w/w, 80/20 P(4HB)/PLLA w/w, 75/25 P(4HB)/PLLA w/w, 70/30 P(4HB)/PLLA w/w, 65/35 P(4HB)/PLLA w/w, 60/40 P(4HB)/PLLA w/w, 55/45 P(4HB)/PLLA w/w, 50/50 P(4HB)/PLLA w/w, 45/55 P(4HB)/PLLA w/w, 40/60 P(4HB)/PLLA w/w, 35/65 P(4HB)/PLLA w/w, and 30/70 P(4HB)/PLLA w/w.
11. The stent of claim 8 , wherein the top coat is substantially free of one or more therapeutic, diagnostic, or prophylactic agents.
12. The stent of claim 1 , wherein the base coat, top coat or combinations thereof comprises a plasticizer at a concentration from about 0 to 10% by weight of the coating.
13. The stent of claim 12 , wherein the plasticizer is triethylcitrate.
14. The stent of claim 1 , wherein the stent is a metallic stent.
15. The stent of claim 1 , wherein the stent has improved surface integrity compared to a coating containing only PLLA.
16. The stent of claim 1 , wherein the polymeric base coat, top coat, or combinations thereof, degrade in less than two years.
17. A method of making the stent of claim 1 , the method comprising coating a stent with a base coat comprising a blend of P(4HB), PLLA, and one or more therapeutic, diagnostic, or prophylactic agents, and optionally coating the base coat with a top coat wherein the base coat comprises one or more nanoparticulate or microparticulate agents, wherein the stent
has a radial recoil of less than 10%,
is expandable rapidly in vivo using a balloon pressure of 4 to 16 bar without cracking of the stent or stent base coat, or other mechanical failure
does not exhibit any significant creep at 100 mmHg for 7 days,
does not shorten significantly upon expansion; and
has struts, constructed with smooth strut edges with strut thicknesses of less than 300 microns.
18. A method of deploying the stent of claim 1 comprising mounting the stent on a delivery system and balloon-expanding the stent inside the body lumen, wherein the stent comprises a base coat and optionally a top coat,
wherein the base coat comprises a blend of poly-4-hydroxybutyrate (P(4HB)), and poly(L-lactide) (PLLA), and one or more nanoparticulate or microparticulate agents, and wherein the stent,
has a radial recoil of less than 10%,
is expandable rapidly in vivo using a balloon pressure of 4 to 16 bar without cracking of the stent or stent base coat, or other mechanical failure
does not exhibit any significant creep at 100 mmHg for 7 days,
does not shorten significantly upon expansion; and has struts, with smooth strut edges with strut thicknesses of less than 300 microns.
19. The method of claim 12 , wherein the plasticizer concentration is between 0 and 5% by weight of the coating.